Bispecific T-Cell Engaging Antibody

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses some of the new treatments in the pipeline for multiple myeloma.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses research regarding novel relapsed refractory multiple myeloma treatments presented at the ASH Annual Meeting and Exposition.

In this video, Hossein Borghaei, DO, MS, discusses safety, response and survival data of patients with small cell lung cancer who received tarlatamab, a half-life extended bispecific T-cell engager, or HLE BiTE.

The advent of novel therapies has propelled, and continues to propel, tremendous progress and innovation in diffuse large B-cell lymphoma.

In this video, Amrita Krishnan, MD, director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope Cancer Center, discusses the progress in multiple myeloma highlighted at ASCO Annual Meeting.